FDA grants breakthrough status to Eisai and Biogen’s Alzheimer’s drug
The breakthrough designation is based on positive data from the Phase IIb Study 201 trial in Alzheimer’s patients.
Drug Development
GSK to boost growth with Consumer Healthcare business spin-off
The separation, set to occur next year, will provide New GSK with a dividend of...
HIV treatment: are long-acting therapies the future?
Long-acting dosing regimens can make HIV treatment more convenient and reduce the burden of living...
Tiziana and FHI Clinical work on Phase II intranasal Covid-19 drug trial
The trial will monitor the attenuation of pulmonary pathology in 80 participants enrolled at up...
ViiV Healthcare and Halozyme partner to develop long-acting HIV therapies
ViiV Healthcare and Halozyme plan to start experiments with ENHANZE by year-end for the drug...
Centessa Pharmaceuticals: forging a new path for pharma R&D
Centessa Pharmaceuticals, a company trying out an unorthodox approach to R&D, rounds up some of its star acquisitions.
Fujitsu to study Covid-19 treatments using supercomputer Fugaku
Fugaku will be used to discover small molecule inhibitory compounds and study molecular mechanism in hindering Covid-19.
FDA approves Boehringer’s oral blood thinner Pradaxa for children
Pradaxa, initially authorised in 2010, is the first oral blood thinner approved by the FDA for children.
Arrowhead and Horizon enter up to $700m deal to develop RNAi drug
Arrowhead will get an upfront payment of $40m from Horizon in exchange for a global licence to the siRNA therapeutic.
Tonix to develop TNX-102 SL for long Covid treatment
In the third quarter of this year, Tonix will discuss Phase II trial design to assess the drug for long Covid with the US FDA.
Sanofi’s Aubagio obtains EC approval for paediatric multiple sclerosis
The EC granted approval based on positive results from the Phase III TERIKIDS trial of Aubagio in kids with RRMS.
